Prokidney corroborates the mechanism of action of react™ with cell marker analysis in patients with diabetic chronic kidney disease

Winston-salem, n.c., june 23, 2022 (globe newswire) -- prokidney lp (prokidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (ckd) and the prevention of end-stage renal disease (esrd) requiring dialysis or transplant, today published data from a patient study confirming the mechanistic action of its lead candidate react™ with cell marker analysis.
PROK Ratings Summary
PROK Quant Ranking